Rocket's $279.4m cash runs to Q3 2028 as FDA agrees Danon study design
The gene therapy developer reported a $49.2m quarterly loss while setting a mid-2027 target for finishing dosing in its pivotal Danon disease study.
Rocket Pharmaceuticals says its current cash should cover operating costs until the third quarter of 2028. The company disclosed $279.4m in cash alongside a net loss of $49.2m for the third quarter of 2026, in results published on 12 November 2026.
The company also reported that the US Food and Drug Administration has agreed with it on how the pivotal Phase 2 trial of RP-A501, its Danon disease candidate, should be designed. Rocket expects to finish dosing patients in that trial by mid-2027. The material available does not specify endpoints, enrolment size or a filing timetable.
On the commercial side, Rocket said KRESLADI is ready for market and that two Qualified Treatment Centers have been activated. No information was provided on launch timing, pricing, reimbursement or which centres are involved, so it is not yet possible to size any revenue contribution.
Rocket has also begun dosing in a Phase 1 trial of RP-A701 for dilated cardiomyopathy linked to the BAG3 gene. The European Commission has granted the candidate orphan designation. As general context, EU orphan status is reserved for medicines aimed at rare, serious conditions and can carry development incentives. The programme remains at an early stage.
Why it matters
- A cash runway into Q3 2028 gives Rocket funding cover across the planned Danon dosing milestone, though the company did not link the runway to any specific launch or revenue assumptions.
- Agreement with the FDA on trial design removes one regulatory unknown for RP-A501, but missing details on endpoints and sample size limit outside assessment.
- Two activated Qualified Treatment Centers suggest KRESLADI will be delivered through a limited network of sites, which access and supply planners may need to track.
- RP-A701's EU orphan designation adds a European regulatory marker to a Phase 1 pipeline asset.
Company's press release (SEC filing): Rocket Pharmaceuticals, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
